Amgen Readies Cholesterol Drug After Results From Trial
This article is for subscribers only.
Amgen Inc. completed a fifth late-stage study of its experimental anti-cholesterol medicine, leading competitors that are trying to bring a new class of therapies to a market estimated to be worth billions.
The new treatments target a protein called PCSK9 that’s associated with high levels of LDL, or “bad,” cholesterol. Amgen’s drug, evolocumab, met the study goals, enabling the company to proceed with an application for approval this year from regulators, Thousand Oaks, California-based Amgen said yesterday in a statement.